Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: A combined 13C hyperpolarized magnetic resonance and echocardiography study

Diabetes

Volumn 64, Issue 8, 2015, Pages 2735-2743

  Page, Lydia M Le ^a   Rider, Oliver J ^b   Lewis, Andrew J ^b   Ball, Vicky ^a   Clarke, Kieran ^a   Johansson, Edvin ^c   Carr, Carolyn A ^a   Heather, Lisa C ^a   Tyler, Damian J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; DICHLOROACETIC ACID; PYRUVATE DEHYDROGENASE; GLUCOSE BLOOD LEVEL; INSULIN; LIPID; PYRUVATE DEHYDROGENASE COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEART FUNCTION; INSULIN RELEASE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; DIABETIC CARDIOMYOPATHIES; ECHOGRAPHY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DICHLOROACETIC ACID; ECHOCARDIOGRAPHY; INSULIN; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PYRUVATE DEHYDROGENASE COMPLEX; RATS; RATS, WISTAR;

EID: 84977838083     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1560     Document Type: Article

References (57)

1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2):S14-S21.
2. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008;121:748-757.
3. Fein FS. Diabetic cardiomyopathy. Diabetes Care 1990;13:1169-1179.
4. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977;60:884-899.
5. Cosyns B, Droogmans S, Weytjens C, et al. Effect of streptozotocin-induced diabetes on left ventricular function in adult rats: An in vivo Pinhole Gated SPECT study. Cardiovasc Diabetol 2007;6:30.
6. Rajan SK, Gokhale SM. Cardiovascular function in patients with insulindependent diabetes mellitus: A study using noninvasive methods. Ann N Y Acad Sci 2002;958:425-430.
7. Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev 2014;19:35-48.
8. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997;34:25-33.
9. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988;37:1020-1024.
10. Mazumder PK, O'Neill BT, Roberts MW, et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004;53:2366-2374.
11. Chatham JC, Forder JR. Relationship between cardiac function and substrate oxidation in hearts of diabetic rats. Am J Physiol 1997;273:H52-H58.
12. Heather LC, Clarke K. Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 2011;50:598-605.
13. Bell DS. Diabetic cardiomyopathy. Diabetes Care 2003;26:2949-2951.
14. Schilling JD, Mann DL. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin 2012;8:619-631.
15. Neubauer S. The failing heart- An engine out of fuel. N Engl J Med 2007; 356:1140-1151.
16. Hall JL, Stanley WC, Lopaschuk GD, et al. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol 1996;271:H2320-H2329.
17. Seymour AM, Chatham JC. The effects of hypertrophy and diabetes on cardiac vs. activity. J Mol Cell Cardiol 1997;29:2771-2778.
18. Stacpoole PW, Greene YJ. Dichloroacetate. Diabetes Care 1992;15:785-791.
19. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998;329:191-196.
20. Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 2007;15:992-1004.
21. Nicholl TA, Lopaschuk GD, McNeill JH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am J Physiol 1991;261: H1053-H1059.
22. Wall SR, Lopaschuk GD. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim Biophys Acta 1989;1006:97-103.
23. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal- To-noise ratio of . 10, 000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003;100: 10158-10163.
24. Atherton HJ, Schroeder MA, Dodd MS, et al. Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS. NMR Biomed 2011;24:201-208.
25. Mansor LS, Gonzalez ER, Cole MA, et al. Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin. Cardiovasc Diabetol 2013;12:136.
26. Reed MJ, Meszaros K, Entes LJ, et al. A new rat model of type 2 diabetes: The fat-fed, streptozotocin- Treated rat. Metabolism 2000;49:1390-1394.
27. Tyler DJ, Schroeder MA, Cochlin LE, Clarke K, Radda GK. Application of hyperpolarized magnetic resonance in the study of cardiac metabolism. Appl Magn Reson 2008;34:523-531.
28. Schroeder MA, Cochlin LE, Heather LC, Clarke K, Radda GK, Tyler DJ. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc Natl Acad Sci U S A 2008;105:12051-12056.
29. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am J Physiol Heart Circ Physiol 2001;280:H977-H983.
30. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12:141-152.
31. Zierhut ML, Yen YF, Chen AP, et al. Kinetic modeling of hyperpolarized 13C1- pyruvate metabolism in normal rats and TRAMP mice. J Magn Reson 2010;202:85-92.
32. Atherton HJ, Dodd MS, Heather LC, et al. Role of pyruvate dehydrogenase inhibition in the development of hypertrophy in the hyperthyroid rat heart: A combined magnetic resonance imaging and hyperpolarized magnetic resonance spectroscopy study. Circulation 2011;123:2552-2561.
33. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
34. Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 2004;1015:202-213.
35. Kolter T, Uphues I, Eckel J. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol 1997;273:E59-E67.
36. Randle PJ, Kerbey AL, Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: Role of lipid fuels and hormones. Diabetes Metab Rev 1988;4:623-638.
37. Bryson JM, Cooney GJ, Wensley VR, Phuyal JL and Caterson ID. The effects of the inhibition of fatty acid oxidation on pyruvate dehydrogenase complex activity in tissues of lean and obese mice. Int J Obes Relat Metab Disord 1996;20:738-744.
38. Priestman DA, Orfali KA, Sugden MC. Pyruvate inhibition of pyruvate dehydrogenase kinase. Effects of progressive starvation and hyperthyroidism in vivo, and of dibutyryl cyclic AMP and fatty acids in cultured cardiac myocytes. FEBS Lett 1996;393:174-178.
39. Tsutsumi E, Takenaka F. Inhibition of pyruvate kinase by free fatty acids in rat heart muscle. Biochim Biophys Acta 1969;171:355-357.
40. Rider OJ, Cox P, Tyler D, Clarke K, Neubauer S. Myocardial substrate metabolism in obesity. Int J Obes (Lond) 2013;37:972-979.
41. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003;42:328-335.
42. Lamb HJ, Beyerbacht HP, van der Laarse A, et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999;99:2261-2267.
43. Smith IC, Bombardier E, Vigna C, Tupling AR. ATP consumption by sarcoplasmic reticulum Ca2? pumps accounts for 40-50% of resting metabolic rate in mouse fast and slow twitch skeletal muscle. PLoS One 2013;8:e68924.
44. Wu P, Sato J, Zhao Y, Jaskiewicz J, Popov KM, Harris RA. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J 1998;329:197-201.
45. Jeoung NH, Wu P, Joshi MA, et al. Role of pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) in glucose homoeostasis during starvation. Biochem J 2006;397:417-425.
46. Jeoung NH, Harris RA. Pyruvate dehydrogenase kinase-4 deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese mice. Am J Physiol Endocrinol Metab 2008;295:E46-E54.
47. Ussher JR, Wang W, Gandhi M, et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res 2012;94:359-369.
48. Mori J, Alrob OA, Wagg CS, Harris RA, Lopaschuk GD, Oudit GY. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: A critical role of PDK4. Am J Physiol Heart Circ Physiol 2013;304:H1103-H1113.
49. Blackshear PJ, Holloway PA, Alberti KG. The metabolic effects of sodium dichloroacetate in the starved rat. Biochem J 1974;142:279-286.
50. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-1053.
51. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105:1387-1393.
52. Stacpoole PW, Moore GW, Kornhauser DM. Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N Engl J Med 1978;298:526-530.
53. Calcutt NA, Lopez VL, Bautista AD, et al. Peripheral neuropathy in rats exposed to dichloroacetate. J Neuropathol Exp Neurol 2009;68:985-993.
54. Ferriero R, Manco G, Lamantea E, et al. Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis. Sci Transl Med 2013;5: 175ra31.
55. Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatr 2006;95:6-14.
56. Rider OJ, Tyler DJ. Clinical implications of cardiac hyperpolarized magnetic resonance imaging. J Cardiovasc Magn Reson 2013;15:93.
57. Lloyd S, Brocks C, Chatham JC. Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart. Am J Physiol Heart Circ Physiol 2003;285:H163-H172.